A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients With Relapsed / Refractory Lymphoid Malignancies

Trial Profile

A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients With Relapsed / Refractory Lymphoid Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs Nelarabine (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoid leukaemia; Lymphoma; Mantle-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome; T cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Dec 2016 Planned number of patients changed from 35 to 29.
    • 16 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 17 May 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top